Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.67
DRRX's Cash to Debt is ranked higher than
72% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. DRRX: 1.67 )
DRRX' s 10-Year Cash to Debt Range
Min: 0.63   Max: No Debt
Current: 1.67

Equity to Asset 0.47
DRRX's Equity to Asset is ranked higher than
57% of the 754 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. DRRX: 0.47 )
DRRX' s 10-Year Equity to Asset Range
Min: 0.07   Max: 0.96
Current: 0.47

0.07
0.96
F-Score: 5
Z-Score: -6.40
M-Score: -3.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -109.55
DRRX's Operating margin (%) is ranked lower than
51% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.92 vs. DRRX: -109.55 )
DRRX' s 10-Year Operating margin (%) Range
Min: -10882.56   Max: 30.25
Current: -109.55

-10882.56
30.25
Net-margin (%) -111.43
DRRX's Net-margin (%) is ranked lower than
51% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.26 vs. DRRX: -111.43 )
DRRX' s 10-Year Net-margin (%) Range
Min: -10125.58   Max: 30.53
Current: -111.43

-10125.58
30.53
ROE (%) -72.70
DRRX's ROE (%) is ranked lower than
52% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.33 vs. DRRX: -72.70 )
DRRX' s 10-Year ROE (%) Range
Min: -208.92   Max: 81.39
Current: -72.7

-208.92
81.39
ROA (%) -50.23
DRRX's ROA (%) is ranked lower than
52% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.07 vs. DRRX: -50.23 )
DRRX' s 10-Year ROA (%) Range
Min: -55.27   Max: 34.06
Current: -50.23

-55.27
34.06
ROC (Joel Greenblatt) (%) -587.47
DRRX's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.20 vs. DRRX: -587.47 )
DRRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -853.69   Max: 495.79
Current: -587.47

-853.69
495.79
Revenue Growth (%) -25.30
DRRX's Revenue Growth (%) is ranked lower than
51% of the 655 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. DRRX: -25.30 )
DRRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 52.3
Current: -25.3

0
52.3
EBITDA Growth (%) -5.90
DRRX's EBITDA Growth (%) is ranked higher than
62% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. DRRX: -5.90 )
DRRX' s 10-Year EBITDA Growth (%) Range
Min: -35.8   Max: 39.2
Current: -5.9

-35.8
39.2
EPS Growth (%) -6.90
DRRX's EPS Growth (%) is ranked higher than
66% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. DRRX: -6.90 )
DRRX' s 10-Year EPS Growth (%) Range
Min: -28.3   Max: 27.7
Current: -6.9

-28.3
27.7
» DRRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

DRRX Guru Trades in Q3 2013

Robert Bruce 1,215,973 sh (unchged)
Jean-Marie Eveillard 8,508,633 sh (-2.3%)
» More
Q4 2013

DRRX Guru Trades in Q4 2013

Jim Simons 41,054 sh (New)
Jean-Marie Eveillard 10,707,142 sh (+25.84%)
Robert Bruce 1,215,973 sh (unchged)
» More
Q1 2014

DRRX Guru Trades in Q1 2014

Steven Cohen 65,025 sh (New)
Jean-Marie Eveillard 10,707,142 sh (unchged)
Robert Bruce 1,215,973 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

DRRX Guru Trades in Q2 2014

Robert Bruce 1,215,973 sh (unchged)
Jean-Marie Eveillard 10,707,142 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DRRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-12-31 Add 25.84%0.01%$1.25 - $1.75 $ 1.44-5%10707142
Jean-Marie Eveillard 2012-12-31 Add 218.26%0.02%$0.86 - $1.66 $ 1.4429%8657842
Jean-Marie Eveillard 2012-06-30 Add 40.42%$0.71 - $0.95 $ 1.4480%2720409
Jean-Marie Eveillard 2012-03-31 New Buy0.01%$0.7312 - $1.18 $ 1.4492%1937288
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.55
DRRX's P/B is ranked higher than
56% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. DRRX: 6.55 )
DRRX' s 10-Year P/B Range
Min: 1.69   Max: 38.38
Current: 6.55

1.69
38.38
P/S 8.47
DRRX's P/S is ranked higher than
60% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.81 vs. DRRX: 8.47 )
DRRX' s 10-Year P/S Range
Min: 0.93   Max: 17.53
Current: 8.47

0.93
17.53
EV-to-EBIT -7.43
DRRX's EV-to-EBIT is ranked lower than
53% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.17 vs. DRRX: -7.43 )
DRRX' s 10-Year EV-to-EBIT Range
Min: 2.1   Max: 5.8
Current: -7.43

2.1
5.8
Current Ratio 7.02
DRRX's Current Ratio is ranked higher than
92% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. DRRX: 7.02 )
DRRX' s 10-Year Current Ratio Range
Min: 1.48   Max: 29.59
Current: 7.02

1.48
29.59
Quick Ratio 6.23
DRRX's Quick Ratio is ranked higher than
92% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. DRRX: 6.23 )
DRRX' s 10-Year Quick Ratio Range
Min: 1.41   Max: 28.73
Current: 6.23

1.41
28.73

Valuation & Return

vs
industry
vs
history
Price/Net Cash 36.00
DRRX's Price/Net Cash is ranked higher than
86% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DRRX: 36.00 )
DRRX' s 10-Year Price/Net Cash Range
Min: 2.33   Max: 525
Current: 36

2.33
525
Price/Net Current Asset Value 18.00
DRRX's Price/Net Current Asset Value is ranked higher than
82% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DRRX: 18.00 )
DRRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.19   Max: 87.5
Current: 18

2.19
87.5
Price/Tangible Book 8.47
DRRX's Price/Tangible Book is ranked higher than
61% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. DRRX: 8.47 )
DRRX' s 10-Year Price/Tangible Book Range
Min: 1.37   Max: 203
Current: 8.47

1.37
203
Price/Median PS Value 0.94
DRRX's Price/Median PS Value is ranked higher than
85% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.27 vs. DRRX: 0.94 )
DRRX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 10.42
Current: 0.94

0.12
10.42
Earnings Yield (Greenblatt) 13.20
DRRX's Earnings Yield (Greenblatt) is ranked higher than
95% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. DRRX: 13.20 )
DRRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 17.1   Max: 48.2
Current: 13.2

17.1
48.2
Forward Rate of Return (Yacktman) -6.60
DRRX's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. DRRX: -6.60 )
DRRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -23.9   Max: -9.3
Current: -6.6

-23.9
-9.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DC8.Germany
DURECT Corporation was incorporated in Delaware in February 1998. The Company is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its proprietary drug delivery technology platforms. The Company's product pipeline currently consists of seven investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).The Company has other programs underway in fields outside of pain management, including several efforts underway which seek to improve the administration of biotechnology agents such as proteins and peptides. The Company's development efforts are focused on the application of its pharmaceutical systems technologies to potential products in a variety of chronic and episodic disease areas including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases. Its product candidate include Remoxy (Oral controlled release oxycodone); POSIDUR (Controlled release injection of bupivacaine); ELADUR (Transdermal bupivacaine); TRANSDUR-Sufentanil (Transdermal sufentanil); ORADUR-based opioid (hydrocodone); ORADUR-based opioid (hydromorphone); ORADUR-ADHD; ORADUR-based opioid (oxymorphone); and Relday (risperidone). The DURECT Solutions is the Company's developing and commercializing pharmaceutical systems that will deliver the right drug to the right place, in the right amount and at the right time to treat chronic and episodic diseases and conditions. Its pharmaceutical systems enable optimized therapy for a given disease or patient population by controlling the rate and duration of drug administration. The Company has several major technology platforms: Bioerodible Injectable Depot Systems, The TRANSDUR Transdermal Delivery System, The ORADUR Sustained Release Gel Cap Technology, and The DURIN Biodegradable Implant Technology. The manufacture and marketing of its pharmaceutical systems and its research and development activities are subject to extensive regulation for safety, efficacy and quality by numerous government authorities in the United States and abroad.
» More Articles for DRRX

Headlines

Articles On GuruFocus.com
Durect Corp. Reports Operating Results (10-Q) Nov 04 2010 
Durect Corp. Reports Operating Results (10-Q) Aug 05 2010 
Opportunistic Coat-tailing Jan 05 2010 
Durect Corp. Reports Operating Results (10-Q) Nov 02 2009 
Durect Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
DURECT to Present at the Rodman & Renshaw Investment Conference Aug 25 2014
DURECT CORP Financials Aug 19 2014
DRRX: Durect Corp. Offers Favorable Risk / Reward Aug 08 2014
DURECT CORP Files SEC form 10-Q, Quarterly Report Aug 08 2014
DURECT Corp Earnings Call scheduled for 4:30 pm ET today Aug 07 2014
DURECT CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2014
DURECT Corporation Announces Second Quarter 2014 Financial Results and Update of Programs Aug 07 2014
Q2 2014 DURECT Corp Earnings Release - After Market Close Aug 07 2014
DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call Jul 30 2014
Why Durect Corp. (DRRX) Stock Is Jumping Today Jun 27 2014
DURECT CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jun 26 2014
DURECT Secures $20 Million Debt Financing Jun 26 2014
DURECT CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 17 2014
DURECT to Present at The Wall Street Analyst Forum Institutional Investor Conference Jun 09 2014
Theralase Laser Technology Used By Star Athletes for Pain Management Jun 02 2014
DURECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 16 2014
DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the International Anesthesia... May 16 2014
DURECT Announces Participation in Bay Area Prescription Drug Abuse Summit Meeting May 07 2014
Durect Shares Should Double In The Next Year May 03 2014
DURECT CORP Files SEC form 10-Q, Quarterly Report May 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK